Efficacy

Efficacy of Tecentriq (Atezolizumab) in Breast Cancer

Tecentriq (Atezolizumab) is an immune checkpoint inhibitor that has shown efficacy in the treatment of certain types of breast cancer. Specifically, it has been approved for use in combination with chemotherapy for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) that expresses PD-L1. Clinical trials have demonstrated that Atezolizumab, when used in this population, can significantly extend progression-free survival compared to chemotherapy alone. This benefit is particularly notable since triple-negative breast cancer is a more aggressive and difficult-to-treat form of the disease with fewer targeted therapies available.

The IMpassion130 trial, a pivotal study that led to the approval of Tecentriq for TNBC, showed that the addition of Atezolizumab to nab-paclitaxel significantly improved median progression-free survival in PD-L1-positive patients. Furthermore, an improvement in overall survival was observed, although this did not reach statistical significance in the interim analysis. As a result, Tecentriq has become an important option in the management of PD-L1-positive TNBC, offering hope for improved outcomes in this challenging patient population.

Efficacy of Phesgo (pertuzumab, trastuzumab, and hyaluronidase) in Breast Cancer

Phesgo is a combination of two monoclonal antibodies, pertuzumab and trastuzumab, with the enzyme hyaluronidase, and is used for the treatment of HER2-positive breast cancer. This fixed-dose combination is administered subcutaneously and provides a more convenient alternative to the standard intravenous formulations of pertuzumab and trastuzumab. The efficacy of Phesgo in breast cancer has been established in several clinical trials, showing that it is non-inferior to the intravenous administration of pertuzumab and trastuzumab when used in combination with chemotherapy.

The pivotal trial for Phesgo, the FeDeriCa study, demonstrated that the combination led to comparable levels of pertuzumab and trastuzumab in the blood, meeting its primary endpoint of non-inferiority in pharmacokinetics. Moreover, the study showed similar efficacy in terms of pathological complete response rates in patients with early HER2-positive breast cancer. This suggests that Phesgo maintains the proven therapeutic benefits of pertuzumab and trastuzumab while offering patients a quicker and less invasive method of administration. As such, Phesgo has become a valuable treatment option for patients with HER2-positive breast cancer, aiming to improve the quality of life without compromising efficacy.